Who are Estrace® 0.01% cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Premarin, Premarin, Premarin, Estrace 0.01% Vaginal Cream, Estrogen vaginal cream, Estradiol vaginal cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/estrace-0-01-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Estrace® 0.01% cream — Competitive Intelligence Brief

Estrace® 0.01% cream (Estrace® 0.01% cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen replacement therapy. Area: Gynecology / Endocrinology.

phase 3 Estrogen replacement therapy Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Estrace® 0.01% cream (Estrace® 0.01% cream) — Mylan Pharmaceuticals Inc. Estrace cream delivers estradiol, a natural estrogen, directly to vaginal and vulvar tissues to relieve symptoms of atrophic vaginitis and urogenital atrophy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estrace® 0.01% cream TARGET	Estrace® 0.01% cream	Mylan Pharmaceuticals Inc	phase 3	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Estrace 0.01% Vaginal Cream	Estrace 0.01% Vaginal Cream	University of California, Irvine	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estrogen vaginal cream	Estrogen vaginal cream	The University of Texas Health Science Center, Houston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha and beta
Estradiol vaginal cream	Estradiol vaginal cream	CONRAD	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen replacement therapy class)

Pfizer · 3 drugs in this class
CONRAD · 1 drug in this class
Mylan Pharmaceuticals Inc · 1 drug in this class
University of California, Irvine · 1 drug in this class
University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estrace® 0.01% cream — Competitive Intelligence Brief. https://druglandscape.com/ci/estrace-0-01-cream. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab